Ratings by Ladenburg Thalmann (Aydin Huseynov)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/15/2026 | Elicio Therapeutics | ELTX | New Coverage | Buy (N/A) |
11.73 (4.71) |
-59.85% | Details | |
| 3/4/2026 | Inhibikase Therapeutics Inc | IKT | New Coverage | Buy (N/A) |
1.91 (2.00) |
4.71% | Details | |
| 10/16/2025 | Immunic Inc. | IMUX | New Coverage | Buy (N/A) |
0.84 (14.87) |
1670.24% | Details | |
| 9/29/2025 | Kala Bio | KALA | Downgrade | Neutral (Buy) |
19.05 (1.35) |
-92.91% | Details | |
| 7/11/2025 | Kala Bio | KALA | New Coverage | Buy (N/A) |
6.90 (19.05) |
176.09% | Details | |
| 3/7/2025 | Ardelyx, Inc | ARDX | New Coverage | Buy (N/A) |
5.32 (5.68) |
6.77% | Details | |
| 2/19/2025 | UroGen Pharma | URGN | New Coverage | Buy (N/A) |
10.56 (29.40) |
178.41% | Details | |
| 12/5/2024 | Cellectar Biosciences | CLRB | New Coverage | Buy (N/A) |
1.47 (3.20) |
117.69% | Details | |
| 9/16/2024 | Compass Therapeutics | CMPX | Upgrade | Buy (Neutral) |
1.65 (2.19) |
32.73% | Details | |
| 9/16/2024 | Corvus Pharmaceuticals | CRVS | Maintain | Buy (N/A) |
|
Details | ||
| 9/16/2024 | Acrivon Therapeutics Inc | ACRV | Upgrade | Buy (Neutral) |
8.91 (1.98) |
-77.78% | Details | |
| 6/27/2024 | Calidi Biotherapeutics Inc | CLDI | New Coverage | Buy (N/A) |
0.20 (0.15) |
-25% | Details | |
| 6/17/2024 | Coeptis Therapeutics Holdings, Inc. | COEP | Downgrade | Neutral (Buy) |
0.33 (16.40) |
4869.7% | Details | |
| 5/29/2024 | Palisade Bio Inc. | PALI | Maintain | Buy (N/A) |
|
Details | ||
| 5/14/2024 | Capricor Therapeutics | CAPR | Maintain | Buy (N/A) |
|
Details | ||
| 4/30/2024 | Marker Therapeutics | MRKR | New Coverage | Buy (N/A) |
4.12 (1.60) |
-61.17% | Details | |
| 4/29/2024 | Acrivon Therapeutics Inc | ACRV | Downgrade | Neutral (Buy) |
8.46 (1.98) |
-76.6% | Details | |
| 4/18/2024 | Aileron Therapeutics Inc | ALRN | Maintain | Buy (N/A) |
|
Details | ||
| 4/5/2024 | Acrivon Therapeutics Inc | ACRV | Maintain | Buy (N/A) |
|
Details | ||
| 3/14/2024 | Spruce Biosciences, Inc. | SPRB | Downgrade | Neutral (Buy) |
5.19 (50.87) |
880.15% | Details | |
| 2/8/2024 | Biodexa Pharmaceuticals Plc. | BDRX | New Coverage | Buy (N/A) |
1.35 (2.59) |
91.85% | Details | |
| 12/27/2023 | PMV Pharmaceuticals Inc. | PMVP | New Coverage | Buy (N/A) |
3.08 (1.24) |
-59.74% | Details | |
| 12/1/2023 | Aileron Therapeutics Inc | ALRN | Upgrade | Buy (Neutral) |
2.12 (2.11) |
-0.47% | Details | |
| 10/10/2023 | Zura Bio Ltd. | ZURA | New Coverage | Buy (N/A) |
6.93 (5.33) |
-23.09% | Details | |
| 9/22/2023 | Coeptis Therapeutics Holdings, Inc. | COEP | New Coverage | Buy (N/A) |
0.94 (0.33) |
-64.89% | Details | |
| 7/10/2023 | Corvus Pharmaceuticals | CRVS | Maintain | Buy (N/A) |
|
Details | ||
| 6/5/2023 | Alterity Therapeutics | ATHE | Maintain | Buy (N/A) |
|
Details | ||
| 5/30/2023 | Corvus Pharmaceuticals | CRVS | Maintain | Buy (N/A) |
|
Details | ||
| 4/27/2023 | Acrivon Therapeutics Inc | ACRV | New Coverage | Buy (N/A) |
12.52 (1.98) |
-84.19% | Details | |
| 3/15/2023 | Bellicum Pharmaceuticals | BLCM | Downgrade | Neutral (Buy) |
0.86 (0.62) |
-27.91% | Details | |
| 3/10/2023 | Quoin Pharmaceuticals | QNRX | Downgrade | Neutral (Buy) |
0.53 (4.59) |
766.04% | Details | |
| 3/7/2023 | Adverum Biotechnologies | ADVM | New Coverage | Buy (N/A) |
0.77 (4.36) |
466.23% | Details | |
| 2/22/2023 | Aileron Therapeutics Inc | ALRN | Downgrade | Neutral (Buy) |
1.46 (2.11) |
44.52% | Details | |
| 1/31/2023 | Palisade Bio Inc. | PALI | Maintain | Buy (N/A) |
|
Details | ||
| 11/15/2022 | Calithera Biosciences | CALA | Downgrade | Neutral (Buy) |
2.82 (0.00) |
-100% | Details | |
| 11/14/2022 | Compass Therapeutics | CMPX | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2022 | Quoin Pharmaceuticals | QNRX | Maintain | Buy (N/A) |
|
Details | ||
| 11/4/2022 | NextCure Inc. | NXTC | Downgrade | Neutral (Buy) |
2.51 (1.76) |
-29.88% | Details | |
| 10/26/2022 | Capricor Therapeutics | CAPR | New Coverage | Buy (N/A) |
5.73 (22.23) |
287.96% | Details | |
| 10/7/2022 | Corvus Pharmaceuticals | CRVS | New Coverage | Buy (N/A) |
0.88 (16.36) |
1759.09% | Details | |
| 8/31/2022 | Satsuma Pharmaceuticals | STSA | New Coverage | Buy (N/A) |
6.32 (1.10) |
-82.59% | Details | |
| 8/23/2022 | Allarity Therapeutics Inc. | ALLR | Downgrade | Neutral (Buy) |
1.52 (1.18) |
-22.37% | Details | |
| 8/15/2022 | SELLAS Life Sciences Group | SLS | Maintain | Buy (N/A) |
|
Details | ||
| 8/3/2022 | Alterity Therapeutics | ATHE | New Coverage | Buy (N/A) |
0.60 (4.41) |
635% | Details | |
| 7/27/2022 | Anebulo Pharmaceuticals | ANEB | New Coverage | Buy (N/A) |
3.05 (0.36) |
-88.2% | Details | |
| 7/13/2022 | Nuvectis Pharma | NVCT | New Coverage | Buy (N/A) |
12.69 (19.27) |
51.85% | Details | |
| 6/13/2022 | Aileron Therapeutics Inc | ALRN | New Coverage | Buy (N/A) |
0.41 (2.11) |
414.63% | Details | |
| 5/11/2022 | Calithera Biosciences | CALA | Maintain | Buy (N/A) |
|
Details | ||
| 5/6/2022 | Quoin Pharmaceuticals | QNRX | New Coverage | Buy (N/A) |
0.81 (4.59) |
466.67% | Details | |
| 5/2/2022 | Annovis Bio Inc. | ANVS | New Coverage | Buy (N/A) |
9.44 (1.95) |
-79.34% | Details | |
| 4/22/2022 | Cognition Therapeutics | CGTX | New Coverage | Buy (N/A) |
3.10 (1.07) |
-65.48% | Details | |
| 4/4/2022 | SELLAS Life Sciences Group | SLS | Maintain | Buy (N/A) |
|
Details | ||
| 4/1/2022 | Calithera Biosciences | CALA | Maintain | Buy (N/A) |
|
Details | ||
| 3/15/2022 | Compass Therapeutics | CMPX | New Coverage | Buy (N/A) |
1.44 (1.65) |
14.58% | Details | |
| 3/8/2022 | Spruce Biosciences, Inc. | SPRB | New Coverage | Buy (N/A) |
1.88 (50.87) |
2605.85% | Details | |
| 3/1/2022 | NextCure Inc. | NXTC | New Coverage | Buy (N/A) |
4.90 (1.76) |
-64.08% | Details | |
| 2/16/2022 | Bellicum Pharmaceuticals | BLCM | New Coverage | Buy (N/A) |
1.45 (0.62) |
-57.24% | Details | |
| 2/7/2022 | SELLAS Life Sciences Group | SLS | New Coverage | Buy (N/A) |
5.41 (14.64) |
170.61% | Details | |
| 2/2/2022 | Palisade Bio Inc. | PALI | New Coverage | Buy (N/A) |
1.23 (1.97) |
60.16% | Details | |
| 1/31/2022 | Calithera Biosciences | CALA | New Coverage | Buy (N/A) |
0.42 (0.00) |
-100% | Details |
